ARL-17477 dihydrochloride hydrate
SIGMA/SML0178 - ≥98% (HPLC)
Synonym: N-
CAS Number: 866914-87-6 (anhydrous)
Empirical Formula (Hill Notation): C20H20ClN3S·2HCl · xH2O
Molecular Weight: 442.83 (anhydrous basis)
MDL Number: MFCD21608518
Linear Formula: C20H20ClN3S·2HCl · xH2O
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to beige |
form | powder |
InChI | 1S/C20H20ClN3S.2ClH.H2O/c |
InChI key | QOPATWWWZNTSQF-UHFFFAOYSA |
originator | AstraZeneca |
Quality Level | 100 ![]() |
SMILES string | O.Cl.Cl.Clc1cccc(CNCCc2cc |
solubility | H2O: ≥5 mg/mL |
storage condition | desiccated |
storage temp. | 2-8°C |
Application: | ARL-17477 dihydrochloride hydrate may be used in cell signaling studies. |
Biochem/physiol Actions: | ARL-17477 is an nNOS specific inhibitor. The IC50 against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury. |
Features and Benefits: | This compound was developed by AstraZeneca ![]() ![]() |
Packaging: | 5, 25 mg in glass bottle |
Symbol | ![]() |
Signal word | Warning |
Hazard statements | H302 - H319 |
Precautionary statements | P301 + P312 + P330 - P305 + P351 + P338 |
Hazard Codes | Xn |
Risk Statements | 22-36 |
Safety Statements | 26 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | 2-8°C |
UNSPSC | 12352200 |